Supercritical Fluid Chromatography (SFC) testing has become an increasingly valuable analytical strategy for pharmaceutical and biotech programs that require fast, selective, and scalable separation of structurally complex molecules. Particularly well suited for chiral compounds, hydrophobic small molecules, and impurity-rich development samples, SFC offers a powerful complement to liquid chromatography by improving throughput, reducing solvent burden, and expanding separation flexibility. BOC Sciences provides comprehensive SFC testing services for drug discovery, preformulation, process development, and analytical troubleshooting. Our team supports method scouting, enantiomeric excess determination, impurity profiling, peak isolation, and SFC-MS-compatible workflows for challenging compounds, helping clients accelerate decision-making with robust, high-quality analytical data.
We develop high-performance SFC methods for stereochemical assessment, optical purity measurement, and difficult enantiomer separations, building on our expertise in chiral analysis and separation.
Our SFC platform supports precise enantiomeric purity testing and stereoisomer differentiation for discovery and development samples, including workflows related to enantiomer identification (HPLC/SFC).
We use SFC to evaluate impurity distributions, product purity, and separation selectivity for compounds that are difficult to resolve by conventional LC, integrated with our broader API analysis capabilities.
For structurally challenging samples, we integrate SFC testing into broader characterization strategies that may include LC-MS testing, orthogonal confirmation, and targeted follow-up studies.
BOC Sciences delivers tailored SFC analytical solutions to resolve stereoisomers, shorten method development cycles, and generate decision-ready data for complex pharmaceutical samples.
We screen diverse stationary phase chemistries to identify the most selective separation environment for enantiomers, diastereomers, regioisomers, and other closely related analytes that challenge conventional chromatographic methods.
Precise control of backpressure, co-solvent gradients, and additive composition allows us to fine-tune retention, selectivity, and peak symmetry for method development programs requiring reproducible analytical performance.
Our workflow is designed for rapid analytical screening across multiple columns and mobile phase conditions, enabling efficient identification of promising SFC methods during early discovery and lead optimization programs.
SFC is deployed as a complementary platform when HPLC selectivity is limited, helping clients confirm impurity patterns, resolve stereochemical ambiguity, and improve confidence in analytical interpretation.
When analytical results indicate promising separation windows, we can support method translation discussions related to enantiomeric purification (HPLC/SFC) and larger-scale isolation strategy.
Our SFC capabilities are embedded within a broader analytical platform, enabling smooth coordination across chromatographic, spectrometric, and structure-supporting workflows for complex projects.
BOC Sciences provides SFC testing services for a broad range of pharmaceutical and chemical samples. Our workflows are especially useful for compounds requiring chiral discrimination, fast impurity resolution, or alternative selectivity beyond standard reversed-phase methods.
Share your structure, chromatographic challenge, or target separation goal. Our scientists will design an SFC testing strategy tailored to your compound class, stereochemical complexity, and analytical objectives.
We review molecular structure, stereochemical context, physicochemical behavior, solubility characteristics, and the analytical question to determine whether SFC is the most efficient route for your project.
Our scientists screen stationary phases, organic modifiers, additives, gradient settings, pressure, and temperature to identify conditions that deliver the required retention, resolution, and analytical reproducibility.
We assess chromatographic performance, peak assignment confidence, and separation fitness, and where needed, connect the output to complementary workflows such as analytical method development or orthogonal structural follow-up.
We deliver clear analytical findings with project-relevant interpretation, including separation suitability, stereochemical insights, impurity observations, and practical recommendations for follow-up testing or purification strategy.
Many discovery and development teams need rapid enantiomeric information without lengthy reversed-phase screening. BOC Sciences uses structured SFC scouting to identify selective chiral conditions quickly, enabling efficient assessment of optical purity, stereochemical drift, and synthetic route performance.
When HPLC provides insufficient selectivity or unacceptably long run times, SFC can offer an alternative separation mechanism. Our scientists evaluate whether SFC can improve retention behavior, resolve co-eluting peaks, and provide cleaner interpretability for complex sample sets.
Structurally related impurities, isomers, and late-stage synthetic byproducts can be difficult to distinguish by a single analytical approach. We use SFC to sharpen selectivity and, where necessary, support deeper investigation through impurity isolation and identification strategies.
Lipophilic and weakly polar compounds may perform inconsistently in conventional aqueous LC workflows. Our SFC testing services are designed to improve analytical tractability for these samples, helping clients obtain robust retention and meaningful chromatographic resolution with less trial-and-error.
Collaborate with BOC Sciences for high-value SFC method development, chiral separation testing, and impurity-focused analytical support tailored to modern pharmaceutical R&D.
We understand the analytical complexity of enantiomeric and stereoisomeric separations and build SFC workflows that are tailored to pharmaceutical chiral challenges rather than generic chromatography screening.
Our structured screening approach helps reduce unproductive experimentation and identifies practical SFC conditions faster for difficult molecules, development samples, and impurity-rich matrices.
SFC results are interpreted within the larger needs of your program, whether that means stereochemical confirmation, impurity resolution, purification planning, or broader chromatographic troubleshooting.
We do not force a single workflow onto every sample. Each project is designed around your compound class, separation objective, and downstream development priorities.
Client Needs: A small-molecule discovery team needed rapid enantiomeric purity testing for a heteroaryl alcohol scaffold generated during lead optimization. Conventional achiral LC could not distinguish the desired isomeric profile, and the project required fast SAR-supportive data.
Challenges: The compound set included closely related analogs with varying basicity and steric bulk, making retention behavior inconsistent across standard screening conditions and complicating a one-method-fits-all approach.
Solution: BOC Sciences conducted targeted chiral SFC screening across multiple stationary phases with controlled modifier and additive variation. We optimized backpressure, temperature, and gradient shape to improve selectivity while maintaining short analytical cycles. The final workflow enabled reliable ee determination and clear resolution of the target enantiomer pair.
Outcome: The client obtained a robust SFC method suitable for routine stereochemical monitoring across the compound series, supporting faster decision-making during medicinal chemistry iteration.
Client Needs: A development-stage program required separation of a lipophilic API candidate from a structurally similar process impurity that repeatedly co-eluted under legacy HPLC conditions.
Challenges: The analytes showed similar UV response and comparable LC retention, while the impurity level was low enough to make method selectivity, not detector sensitivity, the dominant challenge.
Solution: We repositioned the problem as an orthogonal SFC selectivity study and screened multiple column chemistries with controlled alcohol modifier composition. The optimized SFC method created a clear separation window between the main peak and the process impurity and improved peak symmetry for more dependable integration.
Outcome: The client gained a practical impurity-monitoring method that resolved the co-elution issue and supported more confident process evaluation and sample release decisions within development workflows.
Client Needs: A pharmaceutical client had a hydrophobic chiral intermediate that produced broad peaks, long run times, and poor reproducibility by reversed-phase HPLC. They needed a better analytical route for routine sample assessment.
Challenges: The molecule exhibited weak aqueous compatibility and unstable retention under the client's previous method, making troubleshooting time-consuming and limiting throughput.
Solution: BOC Sciences redesigned the analytical approach using SFC, selecting a column chemistry better matched to the intermediate's polarity profile and stereochemical features. We optimized pressure, modifier strength, and gradient behavior to stabilize retention and improve peak efficiency without overcomplicating the workflow.
Outcome: The rescued SFC method delivered faster analysis, cleaner peak shapes, and better reproducibility, giving the client a practical platform for routine intermediate tracking and continued development work.
SFC testing is gaining increasing attention in drug development because it can efficiently support the separation and analysis of complex molecules, especially in key applications such as chiral compound analysis, impurity profiling, and early-stage method screening. For many R&D teams, traditional liquid chromatography methods may have limitations in selectivity, analytical efficiency, or flexibility during method switching, while SFC often offers a broader condition space for compound screening and separation. As a result, in lead optimization, candidate characterization, and process-related studies, SFC testing is widely regarded as an important analytical approach for improving both development efficiency and data quality.
SFC testing is especially suitable for compounds with low to moderate polarity, structurally complex molecules, isomers, or samples requiring high separation selectivity, making it particularly valuable in small molecule drug development. Examples include chiral drugs, intermediates, degradation-related components, synthetic byproducts, and samples in method development that require rapid comparison of separation conditions. For drug development teams, this means that when facing difficult separation challenges, SFC is not merely an alternative technique, but often an effective tool for overcoming method development bottlenecks and improving analytical resolution.
SFC testing and HPLC are not simply interchangeable techniques, but complementary analytical platforms with distinct strengths. HPLC remains highly effective for many routine analytical tasks, while SFC often demonstrates stronger selectivity in chiral separations, isomer discrimination, and rapid screening of certain complex samples. For drug development clients, the best strategy is usually not to commit to one platform too early, but to evaluate the analytical route based on molecular properties, project goals, and separation challenges. Service providers such as BOC Sciences, with experience across multiple analytical platforms, can help select a more suitable testing strategy and support clients in establishing a more productive analytical pathway.
In chiral compound development, researchers are often most concerned with enantiomeric separation performance, screening efficiency, and the future usability of the analytical method, and SFC testing offers clear advantages in these areas. By combining multiple chiral columns with flexible mobile phase systems, SFC can provide a wider range of options for enantiomer separation, which is why it is frequently used for early-stage screening, method feasibility assessment, and condition optimization. For clients involved in innovative drug discovery, complex intermediates, or specialized chemistry programs, introducing SFC testing early can help generate a clearer understanding of sample behavior and reduce repeated trial-and-error during later analytical development.
Evaluating an SFC testing provider requires more than checking whether they can simply perform the test; it is more important to assess whether they truly understand the analytical needs of drug development projects. A professional provider should have experience with multiple sample types and be able to offer logical technical strategies for chiral separations, impurity analysis, method screening, and other challenging applications, while also delivering data that can support research decisions. At BOC Sciences, for example, we provide customized analytical services tailored to drug development scenarios, with strong emphasis on sample understanding, method suitability, and effective project communication, helping clients gain more reliable analytical support and greater confidence in collaboration.
We needed an efficient SFC method to evaluate stereochemical consistency in a constrained peptide-related small molecule program. BOC Sciences quickly identified suitable screening conditions and helped us establish a practical analytical workflow for ongoing R&D decision-making.
— Peptide R&D Project Manager, a U.S. Biotechnology Company
Our internal LC methods could not adequately separate one critical process-related impurity from the main compound. The BOC Sciences team proposed an SFC-based strategy, optimized the separation conditions, and provided clear, actionable analytical insight for our development program.
— Senior Analytical Scientist, a European Small Molecule Drug Developer
What impressed us most was their ability to connect chromatographic performance with actual project needs. Their SFC method development work gave our chemistry team a more reliable way to assess enantiomeric purity across a series of discovery-stage intermediates.
— Director of Medicinal Chemistry, a U.K. Biopharmaceutical Company
We were looking for an orthogonal separation approach for a lipophilic candidate that performed poorly by conventional HPLC. BOC Sciences used SFC in a focused and technically sound way, helping us clarify impurity behavior and improve our broader analytical strategy.
— CMC Analytical Lead, a U.S. Specialty Pharma Company
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
